Antibiotic Susceptibility Profile and Emerging Resistance in Neonatal Sepsis at a Nigerian Tertiary Centre: Implications for Empirical Therapy
This study at a Nigerian tertiary hospital reveals that Gram-negative bacteria, particularly *Escherichia coli*, are the predominant causes of neonatal sepsis with alarmingly high resistance to ampicillin and third-generation cephalosporins, necessitating an urgent revision of empirical antibiotic guidelines toward agents like ciprofloxacin, gentamicin, and amikacin while balancing safety concerns.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the first month of life, a newborn's body is a work in progress. Their immune system, the internal defense force that fights off invaders, is still learning its job. It lacks the full strength and experience of an adult's, making these tiny patients uniquely vulnerable to infections that can spread quickly through the blood. When such an infection takes hold, it is called sepsis, a condition that can turn fatal within hours if not treated immediately. Because symptoms in newborns are often vague—like a fever, trouble breathing, or simply refusing to eat—doctors cannot wait for lab results to confirm the specific germ causing the illness. They must act fast, choosing a medicine that they hope will kill the bug. This is known as empirical therapy: treating based on the most likely culprit rather than a confirmed diagnosis. However, this strategy relies on a fragile assumption: that the bacteria causing the infection will still be killed by the standard drugs doctors reach for. In many parts of the world, that assumption is breaking down as bacteria evolve to resist the very medicines designed to stop them.
Researchers at the Federal Teaching Hospital in Owerri, Nigeria, set out to see if this breakdown was happening in their own neonatal unit. They wanted to know which germs were actually causing sepsis in their newborns and whether the antibiotics they were currently using would still work. Between June 2023 and February 2024, they followed 75 newborns who were admitted with signs of infection. For each baby, they drew a small amount of blood and placed it in a special machine that watches for microbial growth, a method that is more sensitive than older techniques. Once a germ was found, they identified exactly what it was and then tested it against a wide range of antibiotics to see which ones could stop it and which ones it could shrug off.
The results painted a clear and concerning picture. Out of the 75 babies, 55 had a confirmed bacterial infection. The vast majority of these infections were caused by a group of germs known as gram-negative bacteria, with Escherichia coli being the most common offender, followed by Staphylococcus species and Klebsiella pneumoniae. The researchers also noticed a pattern in when these infections appeared. The gram-negative bacteria were more likely to strike very early in a baby's life, often within the first three days, suggesting they were passed from the mother during birth. In contrast, the gram-positive bacteria, like Staphylococcus, were more common in infections that appeared later, after the baby had spent some time in the hospital. This distinction is vital because it tells doctors where the germs are coming from and how they are spreading.
The most critical finding, however, was about the drugs. The study revealed that the standard first-line antibiotics used in many hospitals were largely ineffective against the germs found in this unit. Resistance to ampicillin was nearly universal, affecting more than 90 percent of the bacteria tested. The situation was equally dire for a class of drugs called third-generation cephalosporins, which are often the go-to treatment for serious infections; resistance rates for these drugs hovered between 80 and 90 percent. In simpler terms, if a doctor prescribed these common medicines, they would likely be fighting a losing battle against the specific bacteria circulating in this hospital. The study found that E. coli was responsible for the majority of the fatalities, accounting for four out of six deaths (66.7%), while gram-negative organisms as a group caused the majority of deaths overall (83.3%).
Despite these grim statistics, the researchers did find a few antibiotics that still held their ground. Ciprofloxacin, gentamicin, and amikacin showed the best ability to kill the bacteria in the lab tests. Ciprofloxacin, in particular, was effective against 73.7% of the E. coli samples and 100% of the Klebsiella samples. However, the authors caution that using these drugs in newborns requires careful thought. While gentamicin and amikacin have a well-established safety record for infants, ciprofloxacin is sometimes avoided in very young children due to concerns about how it might affect developing joints, though recent evidence suggests it can be used safely when the benefits outweigh the risks. The high resistance to the older, safer drugs means that doctors in this region may need to change their approach, potentially using these more potent but carefully monitored antibiotics as their first choice.
The study concludes that the current rules for treating newborn sepsis in this hospital are outdated. The germs have changed, and the medicines need to change with them. The researchers emphasize that relying on old guidelines or general recommendations from international bodies is no longer enough when local bacteria are evolving so quickly. They argue for a shift toward continuous monitoring of which germs are present and which drugs still work, a practice known as antimicrobial stewardship. Without this constant vigilance and a willingness to update treatment protocols based on local data, the window of opportunity to save these vulnerable lives continues to narrow. The findings serve as a stark reminder that in the fight against infection, what works in one place or one year may not work in the next, and staying ahead of the enemy requires knowing exactly who is on the battlefield.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.